MIMEDX Q2 net sales $99 mln, up 13% YoY, raises 2025 growth expectations.

• MIMEDX reports record Q2 2025 net sales of $99m, up 13% YoY. • GAAP net income and diluted EPS at $10m and $0.06, respectively. • Adjusted EBITDA reaches $24m, or 25% of net sales. • Company raises 2025 net sales growth expectations. • Management to host conference call on July 30, 2025.

MIMEDX (NASDAQ: MDXG) announced its record-breaking second-quarter 2025 financial results, reporting net sales of $99 million, a 13% year-over-year (YoY) increase. The company's GAAP net income reached $10 million, with diluted earnings per share (EPS) at $0.06. Adjusted EBITDA climbed to $24 million, representing 25% of net sales [1].

The company's performance was driven by robust growth across both the Wound and Surgical product segments. Wound product sales grew by 12%, primarily due to the success of CELERA™ and EMERGE™ products. Surgical products saw a 15% increase, with notable contributions from AMNIOFIX®, AMNIOEFFECT®, and HELIOGEN™ [1].

MIMEDX's gross profit margin slightly decreased to 81% from 83% in the prior year, driven by production variances and changes in product mix. Selling, general, and administrative (SG&A) expenses increased to $64 million from $55 million, primarily due to higher sales commissions and legal costs. Research and development (R&D) expenses remained stable at $3 million [1].

The company ended the quarter with $119 million in cash, up $12 million from the previous quarter and $15 million from year-end 2024. Management raised its 2025 net sales growth expectations to the low double-digits and maintained Adjusted EBITDA margin projections above 20% [1].

MIMEDX will host a conference call on July 30, 2025, at 4:30 PM ET to discuss its second-quarter 2025 results. The call can be accessed using the following information: Webcast: Click here; U.S. Investors: 877-407-6184; International Investors: 201-389-0877; Conference ID: 13754722 [1].

References:
[1] https://www.stocktitan.net/news/MDXG/mimedx-announces-record-second-quarter-2025-operating-and-financial-l0zeywejhxru.html